Rae William, Ward Daniel, Mattocks Christopher J, Gao Yifang, Pengelly Reuben J, Patel Sanjay V, Ennis Sarah, Faust Saul N, Williams Anthony P
Department of Immunology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Southampton NIHR Wellcome Trust Clinical Research Facility, University of Southampton, University Hospital Southampton, Southampton, UK.
Clin Transl Immunology. 2017 Sep 15;6(9):e155. doi: 10.1038/cti.2017.38. eCollection 2017 Sep.
Primary immunodeficiencies (PIDs) are rare inborn errors of immunity that have a heterogeneous phenotype that can include severe susceptibility to life-threatening infections from multiple pathogens, unique sensitivity to a single pathogen, autoimmune/inflammatory (AI/I) disease, allergies and/or malignancy. We present a diverse cohort of monogenic PID patients with and without AI/I diseases who underwent clinical, genetic and immunological phenotyping. Novel pathogenic variants were identified in , , , , and as well as previously reported pathogenic variants in , , , and . AI/I manifestations were frequently encountered in PIDs, including at presentation. Autoimmunity/inflammation was multisystem in those effected, and regulatory T cell (Treg) percentages were significantly decreased compared with those without AI/I manifestations. Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required. Patients with multisystem autoimmunity/inflammation should be investigated for an underlying PID, and in those with PID early assessment of Tregs may help to assess the risk of autoimmunity/inflammation.
原发性免疫缺陷病(PIDs)是罕见的先天性免疫缺陷病,具有异质性表型,可包括对多种病原体的危及生命感染的严重易感性、对单一病原体的独特敏感性、自身免疫/炎症(AI/I)疾病、过敏和/或恶性肿瘤。我们展示了一组不同的单基因PID患者队列,包括有和没有AI/I疾病的患者,他们接受了临床、基因和免疫表型分析。在[具体基因1]、[具体基因2]、[具体基因3]、[具体基因4]、[具体基因5]和[具体基因6]中鉴定出了新的致病变异,以及在[具体基因7]、[具体基因8]、[具体基因9]和[具体基因10]中先前报道的致病变异。AI/I表现经常在PID中出现,包括在初诊时。自身免疫/炎症在受累患者中是多系统的,与没有AI/I表现的患者相比,调节性T细胞(Treg)百分比显著降低。在所有病例中,泼尼松龙被用作一线免疫抑制剂,然而在大多数病例中,类固醇单一疗法未能长期控制自身免疫/炎症,需要额外的免疫抑制。有多系统自身免疫/炎症的患者应检查是否存在潜在的PID,对于患有PID的患者,早期评估Tregs可能有助于评估自身免疫/炎症的风险。